JPWO2019213442A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019213442A5 JPWO2019213442A5 JP2020561726A JP2020561726A JPWO2019213442A5 JP WO2019213442 A5 JPWO2019213442 A5 JP WO2019213442A5 JP 2020561726 A JP2020561726 A JP 2020561726A JP 2020561726 A JP2020561726 A JP 2020561726A JP WO2019213442 A5 JPWO2019213442 A5 JP WO2019213442A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- item
- moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical group 0.000 claims description 263
- 229920001184 polypeptide Polymers 0.000 claims description 108
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 108
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 108
- 108020001507 fusion proteins Proteins 0.000 claims description 63
- 102000037865 fusion proteins Human genes 0.000 claims description 63
- 235000001014 amino acid Nutrition 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 51
- 125000005647 linker group Chemical group 0.000 claims description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 31
- 201000010099 disease Diseases 0.000 claims description 29
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 20
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 18
- 108060003951 Immunoglobulin Proteins 0.000 claims description 18
- 102000018358 immunoglobulin Human genes 0.000 claims description 18
- 208000007502 anemia Diseases 0.000 claims description 11
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 7
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 7
- 210000003734 kidney Anatomy 0.000 claims description 7
- 210000004072 lung Anatomy 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 6
- 238000012986 modification Methods 0.000 claims description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 5
- 235000004279 alanine Nutrition 0.000 claims description 5
- 235000003704 aspartic acid Nutrition 0.000 claims description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 5
- 235000018417 cysteine Nutrition 0.000 claims description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 5
- 230000003993 interaction Effects 0.000 claims description 5
- 239000004474 valine Substances 0.000 claims description 5
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000000833 heterodimer Substances 0.000 claims description 4
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 4
- 208000024985 Alport syndrome Diseases 0.000 claims description 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- 208000002903 Thalassemia Diseases 0.000 claims description 3
- 230000036755 cellular response Effects 0.000 claims description 3
- 208000020832 chronic kidney disease Diseases 0.000 claims description 3
- 208000003215 hereditary nephritis Diseases 0.000 claims description 3
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 3
- 206010028537 myelofibrosis Diseases 0.000 claims description 3
- 201000002793 renal fibrosis Diseases 0.000 claims description 3
- 208000007056 sickle cell anemia Diseases 0.000 claims description 3
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 2
- 208000026372 Congenital cystic kidney disease Diseases 0.000 claims 1
- 208000026292 Cystic Kidney disease Diseases 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 42
- 108090000623 proteins and genes Proteins 0.000 description 42
- 102000004169 proteins and genes Human genes 0.000 description 42
- 239000011230 binding agent Substances 0.000 description 38
- 108091033319 polynucleotide Proteins 0.000 description 19
- 102000040430 polynucleotide Human genes 0.000 description 19
- 239000002157 polynucleotide Substances 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 15
- 239000012634 fragment Substances 0.000 description 12
- 102000016970 Follistatin Human genes 0.000 description 6
- 108010014612 Follistatin Proteins 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 4
- 201000009594 Systemic Scleroderma Diseases 0.000 description 4
- 206010042953 Systemic sclerosis Diseases 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 3
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 3
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 3
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108010023082 activin A Proteins 0.000 description 2
- 108010023079 activin B Proteins 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 208000030761 polycystic kidney disease Diseases 0.000 description 2
- 108010059616 Activins Proteins 0.000 description 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 1
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 description 1
- 102100026818 Inhibin beta E chain Human genes 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 208000000943 scapulohumeral muscular dystrophy Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862666547P | 2018-05-03 | 2018-05-03 | |
| US62/666,547 | 2018-05-03 | ||
| US201862779998P | 2018-12-14 | 2018-12-14 | |
| US62/779,998 | 2018-12-14 | ||
| PCT/US2019/030469 WO2019213442A1 (en) | 2018-05-03 | 2019-05-02 | MULTISPECIFIC BINDERS OF TGFβ-SUPERFAMILY LIGANDS AND USES THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021522793A JP2021522793A (ja) | 2021-09-02 |
| JP2021522793A5 JP2021522793A5 (https=) | 2022-05-13 |
| JPWO2019213442A5 true JPWO2019213442A5 (https=) | 2022-05-13 |
Family
ID=68386158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561726A Pending JP2021522793A (ja) | 2018-05-03 | 2019-05-02 | ＴＧＦβスーパーファミリーリガンドの多特異性バインダーおよびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12103959B2 (https=) |
| EP (1) | EP3788066A4 (https=) |
| JP (1) | JP2021522793A (https=) |
| AU (1) | AU2019262139A1 (https=) |
| CA (1) | CA3099527A1 (https=) |
| WO (1) | WO2019213442A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4073101A4 (en) * | 2019-12-10 | 2024-01-10 | Acceleron Pharma Inc. | SINGLE-ARM ACTRIIA AND ACTRIIB HETEROMULTIMERS AND METHOD FOR TREATING PULMONARY HYPERTENSION |
| KR20230117348A (ko) * | 2020-11-04 | 2023-08-08 | 에이치큐 한 | Tgf-베타 계열의 다중 리간드를 저해할 수 있는 신규한 이작용성 다중특이적 길항제 및 이의 용도 |
| US20240277807A1 (en) * | 2021-06-11 | 2024-08-22 | Acceleron Pharma Inc. | Actrii proteins and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3083324A1 (en) * | 2010-03-05 | 2011-09-09 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| US9676863B2 (en) * | 2014-02-10 | 2017-06-13 | Merck Patent Gmbh | Targeted TGFβ inhibitors |
| JP6631865B2 (ja) * | 2014-08-11 | 2020-01-15 | 日本化薬株式会社 | ＴＧＦβ阻害機能を持つキメラタンパク質 |
| CN107849114B (zh) * | 2015-04-06 | 2021-08-20 | 阿塞勒隆制药公司 | 单臂i型和ii型受体融合蛋白和其用途 |
| US10227392B2 (en) * | 2015-04-06 | 2019-03-12 | Acceleron Pharma Inc. | ALK7:ActRIIB heteromultimers and uses thereof |
| AU2017293778B2 (en) * | 2016-07-07 | 2022-03-24 | Acceleron Pharma Inc. | TGF-beta superfamily heteromultimers and uses thereof |
| JP7280182B2 (ja) | 2016-10-05 | 2023-05-23 | アクセルロン ファーマ インコーポレイテッド | バリアントＡｃｔＲＩＩＢタンパク質およびその使用 |
| US11440949B2 (en) * | 2016-10-05 | 2022-09-13 | Acceleron Pharma Inc. | TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof |
| CN206301918U (zh) * | 2016-12-23 | 2017-07-04 | 深圳国人通信股份有限公司 | 一种介质移相器 |
| CA3099325A1 (en) * | 2018-05-03 | 2019-11-07 | Acceleron Pharma Inc. | Novel binders of tgf.beta.-superfamily ligands and uses thereof |
| EP3807308A4 (en) * | 2018-06-15 | 2022-03-16 | Acceleron Pharma Inc. | BI AND TRIFUNCTIONAL FUSION PROTEINS AND THEIR USES |
-
2019
- 2019-05-02 WO PCT/US2019/030469 patent/WO2019213442A1/en not_active Ceased
- 2019-05-02 US US17/052,785 patent/US12103959B2/en active Active
- 2019-05-02 CA CA3099527A patent/CA3099527A1/en active Pending
- 2019-05-02 EP EP19796599.9A patent/EP3788066A4/en active Pending
- 2019-05-02 JP JP2020561726A patent/JP2021522793A/ja active Pending
- 2019-05-02 AU AU2019262139A patent/AU2019262139A1/en not_active Abandoned
-
2024
- 2024-08-21 US US18/811,531 patent/US20250109179A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023181445A5 (https=) | ||
| JP2016528295A5 (https=) | ||
| JP2019137675A5 (https=) | ||
| JP2021533779A5 (https=) | ||
| EP4151658A1 (en) | Single domain binding molecule | |
| JP2023123649A5 (https=) | ||
| JP2021522795A5 (https=) | ||
| KR20170049319A (ko) | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 | |
| US20230192887A1 (en) | Engineered anti-her2 bispecific proteins | |
| CN119032104A (zh) | 抗血清白蛋白纳米抗体及其衍生物 | |
| US20180280474A1 (en) | Treatment of bile acid disorders | |
| JP2025124718A5 (https=) | ||
| JP2021522793A5 (https=) | ||
| JPWO2020037150A5 (https=) | ||
| JPWO2021185361A5 (https=) | ||
| JPWO2019213446A5 (https=) | ||
| JPWO2019213442A5 (https=) | ||
| JP2025116068A (ja) | 腎臓活性融合タンパク質及びそれを使用する治療方法 | |
| US20260035463A1 (en) | Multispecific antibody and use thereof | |
| JPWO2022129560A5 (https=) | ||
| JPWO2023070056A5 (https=) | ||
| JPWO2021263058A5 (https=) | ||
| JPWO2021168194A5 (https=) | ||
| JPWO2022150788A5 (https=) | ||
| US20240392035A1 (en) | Engineered anti-her2 bispecific proteins |